To enhance the anti-tumor efficacy of KD + CP, with a view to exploit the OXPHOS capacity of MYCN-amplified cells [8], we also treated NB-xenograft-bearing mice with a triple therapy combination of KD, CP, and MET. The gene discussed is MYCN; the disease is neoplasm.